Five-month observation of persistent diabetic macular edema after intravitreal injection of Ozurdex implant

Dominik Zalewski, Dorota Raczyńska, Krystyna Raczyńska, Dominik Zalewski, Dorota Raczyńska, Krystyna Raczyńska

Abstract

Aims: This retrospective analysis was aimed at evaluating the effectiveness of treatment of persistent diabetic macular edema with intravitreal injections of 0.7 mg dexamethasone implant Ozurdex. The study comprised three male patients (6 eyes).

Results: The average thickness of the retina at baseline was 632 μm, the medial BCVA was 0.8 logMAR, and corrected intraocular pressure was 13.7 mmHg. The maximum decrease in mean retinal thickness was observed at four weeks following the treatment and was 365 μm (-267 μm) and visual acuity improved by an average of two lines and was 0.6 logMAR. The largest increase in mean retinal thickness to average of 528 μm (+164 μm) occurred at 16 weeks and the average BCVA was 0.614 lines BCVA logMAR. In one eye, there was a steroid cataract development after the third dose of dexamethasone implant of 0.7 mg.

Conclusions: The intravitreal dexamethasone implant treatment of patients with persistent diabetic macular edema in whom laser photocoagulation proved to be ineffective and as a result they required a monthly injection of anti-VEGF factors (Ranibizumab, Bevacizumab) may be a good alternative to extending the interval of injections. However, reinjections involve a high risk of developing poststeroid cataracts, which is not without significance in middle-aged patients.

Figures

Figure 1
Figure 1
Retinal thickness dependence of the duration of Ozurdex 0.7 mg in the vitreous. Coloured lines refer to the serial numbers of injections from Table 1.
Figure 2
Figure 2
OCT scans: before and one month after intravitreal Ozurdex 0.7 mg injection.
Figure 3
Figure 3
Intravitreal Ozurdex 0.7 mg implant 2 days after injection.

References

    1. Owen LA, Hartnett ME. Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. Current Diabetes Reports. 2013;13(4):476–480.
    1. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Survey of Ophthalmology. 2009;54(1):1–32.
    1. Cho HY, Kang SW, Kim YT, Chung SE, Lee SW. A three-year follow-up of intravitreal triamcinolone acetonie injection and macular laser photocoagulation for diffuse diabetic macular edema. Korean Journal of Ophthalmology. 2012;26(5):362–368.
    1. Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Archives of Ophthalmology. 1991;109(11):1549–1551.
    1. Lee HY, Lee SY, Park JS. Comparison of photocoagulation with combined intravitreal triamcinolone for diabetic macular edema. Korean Journal of Ophthalmology. 2009;23(3):153–158.
    1. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Archives of Ophthalmology. 2009;127(3):245–251.
    1. Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Sears ML, Tarkkanen A, editors. Surgical Pharmacology of the Eye. New York, NY, USA: Raven Press; 1985.
    1. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma & Clinical Immunology. 2013;9, article 30
    1. Weijtens O, van der Sluijs FA, Schoemaker RC, et al. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. American Journal of Ophthalmology. 1997;123(3):358–363.
    1. Goldfien A. Adrenocorticosteroids and adrenocortical antagonists. In: Katzung BG, editor. Basic and Clinical Pharmacology. 6th edition. London, UK: Prentice Hall International; 1995. pp. 592–607.
    1. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB, III, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110(4):681–686.
    1. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109(5):920–927.
    1. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clinical Ophthalmology. 2011;5(1):139–146.
    1. Pacella E, Vestri AR, Muscella R, et al. Preliminary results of an intravitreal dexamethasone implant (Ozurdex) in patients with persistent diabetic macular edema. Clinical Ophthalmology. 2013;2013(7):1423–1428.
    1. Rishi P, Rishi E, Kuniyal L, Mathur G. Short-term results of intravitreal dexamethasone implant (OZURDEX) in treatment of recalcitrant diabetic macular edema: a case series. Oman Journal of Ophthalmology. 2012;5(2):79–82.
    1. Ferrini W, Ambresin A. Intravitreal dexamethasone implant for the treatment of macular edema after retinal vein occlusion in a clinical setting. Klinische Monatsblätter für Augenheilkunde. 2013;230(4):423–426.
    1. Mayer WJ, Wolf A, Kernt M, et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye. 2013;27(7):816–822.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe